Medical Device Global Market Access

Pure Global
  • 5.0 (1)
  • Technology

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.

  1. 21h ago

    MHRA National Alert DSI/2026/007: Quarantining Devices Without UKCA or CE Marks

    This episode examines the UK MHRA's national alert DSI/2026/007, issued on August 10, 2026, which mandates the quarantine of medical devices supplied without the necessary UKCA or CE conformity markings. We break down the patient safety risks posed by non-compliant devices, identify the specific actions required of healthcare providers and distributors, and outline critical lessons for supply chain management and procurement to prevent future incidents. Key Questions: - What is the significance of the MHRA's national alert DSI/2026/007? - Which types of medical devices are affected by this quarantine order? - Why is a missing UKCA or CE mark a critical patient safety concern? - What are the immediate legal and regulatory duties for UK healthcare organizations? - How should distributors respond to the MHRA's directive? - What practical steps can procurement teams take to verify device conformity upon receipt? - How can this incident inform supplier qualification and management processes? - What are the long-term implications for supply chain integrity in the UK MedTech market? Sources: - https://www.gov.uk/government/news/mhra-advises-quarantine-of-medical-devices-supplied-without-appropriate-conformity-markings How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We act as a local representative and help with regulatory strategy, technical dossier submission, and post-market surveillance. Our AI and data tools streamline market research and compliance, helping you access over 30 global markets efficiently. Whether you're a startup or a multinational enterprise, our global reach and local expertise ensure your products meet all necessary standards for faster market access. For help navigating requirements like UKCA marking and supply chain compliance, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

  2. 1d ago

    MHRA Non-Compliant Medical Devices: UK Quarantine Order and Supply Chain Lessons

    The UK's MHRA issued a Device Safety Information alert (DSI/2026/007) on August 10, 2026, ordering an immediate quarantine of six types of medical devices, including scalpels and blood collection sets, that were supplied without the required UKCA or CE conformity markings. This episode breaks down the MHRA's rationale, which focused on the lack of assured safety and quality due to the missing conformity assessment, even without any reported adverse events. We explore the significant market access consequences for manufacturers and distributors and provide practical steps for regulatory and quality teams to ensure supply chain integrity. Key Questions: - What did the UK MHRA's DSI/2026/007 alert require healthcare providers to do? - Which types of medical devices were ordered into quarantine on August 10, 2026? - Why did the MHRA take decisive action without any reported adverse events? - What does this incident reveal about supply chain integrity in the UK medical device market? - How can distributors and importers strengthen their supplier verification processes? - What are the severe market access consequences of failing to have proper conformity markings? - How can manufacturers protect their brand from non-compliant distribution partners? - What practical steps should regulatory and quality teams take in response to this case study? Sources: - https://www.gov.uk/government/news/mhra-advises-quarantine-of-medical-devices-supplied-without-appropriate-conformity-markings - https://www.gov.uk/drug-device-alerts/devices-supplied-without-valid-ukca-slash-ce-conformity-markings-or-certification-remove-from-use-and-place-in-quarantine-dsi-slash-2026-slash-007 - https://pharmacy.biz/mhra-alert-on-medical-devices-that-lack-quality-approval/ - https://www.medregconsulting.com/post/mhra-orders-halt-to-supply-and-use-of-non-compliant-medical-devices How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex global markets like the UK. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative to ensure full compliance with authorities like the MHRA. We help you verify supply chain partners and maintain continuous regulatory monitoring to prevent costly non-compliance issues. By combining local expertise with advanced AI, we streamline market access and protect your brand's integrity. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and device database at https://pureglobal.ai.

  3. 2d ago

    FDA MDUFA VI Fees: Proposed Increases for Overseas Manufacturers

    The US FDA is considering higher user fees for overseas medical device manufacturers under the proposed MDUFA VI agreement for fiscal years 2028-2032. This episode breaks down the key takeaways from the FDA's public meeting on August 10, 2026, including the agency's rationale for the increase, the potential financial impact on non-US firms, and the critical deadlines for submitting public feedback before the proposal goes to Congress in January 2027. Key Questions: - What is MDUFA VI and why is it important for medical device manufacturers? - What specific fee changes are being proposed for overseas facilities? - What was the FDA's rationale for the proposed fee increase? - What are the key dates and deadlines for providing public feedback? - How could these changes impact your company's budget and market access strategy for the US? - What steps should your regulatory team take now to prepare? - Why are foreign establishment inspection costs a central part of this discussion? - When is the final MDUFA VI package expected to be sent to Congress? Sources: - https://www.medtechdive.com/news/mdufa-vi-fda-industry-patient-device-fees/723118/ How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory changes like the FDA's MDUFA VI proposal. We provide strategic guidance on US market access, help you analyze the financial impact of new fee structures, and assist in preparing technical dossiers and submissions. Our combination of local US regulatory expertise and advanced AI technology streamlines the path to market, ensuring you can adapt to new requirements efficiently. Whether you're a startup or a global enterprise, we can help you maintain and expand your presence in the US market. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

  4. 3d ago

    India's Draft Drugs, Medical Devices and Cosmetics Bill 2026: Key Changes for Manufacturers

    This episode covers India's draft Drugs, Medical Devices and Cosmetics Bill 2026, circulated for feedback on August 7, 2026. We discuss its proposal to replace the 1940 Drugs and Cosmetics Act, creating a separate regulatory framework for medical devices, establishing a Medical Devices Technical Advisory Board (MDTAB), and enhancing enforcement powers. We explore the impact on manufacturers and provide practical steps for regulatory teams to prepare for this significant shift in India's MedTech landscape. Key Questions: - What is the new Drugs, Medical Devices and Cosmetics Bill 2026 in India? - How will this bill change the regulation of medical devices in India? - Why is separating device regulation from drug regulation a critical development? - What is the proposed role of the Medical Devices Technical Advisory Board (MDTAB)? - Which companies will be most affected by these new regulations? - What new enforcement powers are being introduced for the regulator? - How does this draft bill impact manufacturers currently operating under the 1940 Act? - What practical steps should regulatory and quality teams take now to prepare? - When can manufacturers expect these changes to come into effect? - How does this align India's regulations with global standards? Sources: - https://gdcclasses.com/drugs-medical-devices-cosmetics-bill-2026/ - https://www.biospectrumindia.com/news/25/24933/9th-india-medical-device-2026-opens-in-new-delhi-to-focus-on-developing-india-as-global-medtech-hub.html - https://www.operonstrategist.com/cdsco-sanctions-1500-new-posts-unveils-key-regulatory-reforms-for-medical-devices/ - https://www.theindianpractitioner.com/new-drugs-bill-seeks-to-rename-dcgi-bring-medical-devices-under-law/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. For companies targeting the Indian market, our experts offer end-to-end support, from developing a regulatory strategy aligned with the new Drugs, Medical Devices and Cosmetics Bill 2026 to managing technical dossier submissions and acting as your local authorized representative. We leverage advanced AI and in-country expertise to help you navigate regulatory transitions efficiently, ensuring your products achieve and maintain compliance. To learn more about how we can accelerate your entry into over 30 global markets, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

  5. 4d ago

    Health Canada MDEL Modernization: Preparing for Phase 2 Changes by December 2026

    Health Canada is implementing Phase 2 of its Medical Device Establishment Licence (MDEL) modernization, with all changes coming into force on December 14, 2026. This episode provides a detailed breakdown of the key amendments published on June 17, 2026. We cover the removal of the MDEL requirement for certain foreign distributors, the new mandate for importers and distributors to provide a supplier list in their applications, and the more prescriptive requirements for documented procedures covering recalls, complaint handling, and distribution records. We provide practical steps for manufacturers, importers, and distributors to ensure compliance before the deadline. Key Questions: - What are the main changes in Phase 2 of Health Canada's MDEL modernization? - When do the new MDEL rules come into force? - Do foreign distributors still need an MDEL to sell in Canada? - What new information must be included in an MDEL application? - How have the requirements for documented procedures changed for importers and distributors? - What specific procedures must MDEL holders update before the December 14, 2026 deadline? - Who is impacted by these regulatory amendments? - What practical steps should my company take to prepare for the 2026 deadline? - How does this change affect the relationship between Canadian importers and foreign suppliers? Sources: - https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/announcements/phase-2-modernize-medical-device-establishment-licensing.html - https://www.gazette.gc.ca/rp-pr/p2/2026/2026-06-17/html/sor-dors110-eng.html - https://qssolutions.ca/blog/mdel-phase-2-amendments-take-effect-december-2026/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access global markets like Canada. Our experts can help you navigate Health Canada's MDEL modernization by performing gap analyses of your procedures, developing regulatory strategies, and ensuring your technical dossiers are compliant. We act as your local representative and use advanced AI to streamline submissions, helping you achieve compliance faster. For support with your Canadian market access strategy, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI regulatory tools and device database at https://pureglobal.ai.

  6. 5d ago

    EU AI Act and Medical Devices: New Compliance Deadline of August 2, 2028

    This episode covers the EU's postponement of the AI Act compliance deadline for high-risk AI medical devices to August 2, 2028. We discuss Regulation (EU) 2026/1744, explaining what this extension means for manufacturers navigating dual compliance under the MDR/IVDR and the AI Act. We offer practical steps for regulatory, quality, and market-access teams to effectively use this extra time to integrate compliance, engage with Notified Bodies, and strengthen their technical documentation. Key Questions: - What is the new EU AI Act compliance deadline for medical devices? - Which regulation officially postponed the application date? - How does the AI Act interact with the MDR and IVDR for high-risk devices? - What are the key requirements for AI systems under the AI Act? - How should manufacturers update their Quality Management System for AI compliance? - What steps should be taken to prepare technical documentation for a dual conformity assessment? - Why is early engagement with Notified Bodies crucial for AI-enabled devices? - What does the AI Act require regarding data governance and transparency? Sources: - https://www.dlapiper.com/en/insights/publications/2026/07/life-sciences-news-in-italy-july-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements like the EU AI Act and MDR/IVDR. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, reducing time to market. We act as your local representative and provide continuous regulatory monitoring to ensure ongoing compliance. Whether you're a startup or a multinational, we streamline your path to global market access. Learn more about our free AI tools and global device database at https://pureglobal.ai, or contact us at info@pureglobal.com and https://pureglobal.com to accelerate your market entry.

  7. 6d ago

    China NMPA's 57 New Medical Device Guidelines: Immediate Impacts for Manufacturers

    On July 21, 2026, China's NMPA released 57 new medical device guidelines, creating immediate compliance challenges for manufacturers. This episode breaks down the immediate impact of these guidelines, covering the new requirements for technical documentation, clinical data, and product testing. We discuss who is affected and outline practical steps for regulatory and quality teams to perform gap assessments and update their submission dossiers for both new and renewing products. Key Questions: - What are the immediate implications of the NMPA's release of 57 new guidelines on July 21, 2026? - Which types of medical devices are most affected by these new technical review standards? - How do these guidelines impact requirements for clinical data and testing reports for China submissions? - What steps should manufacturers take to conduct a gap assessment against the new NMPA requirements? - How will these changes affect the timeline for both new product registrations and renewals in China? - Why is it critical to review your product portfolio immediately to identify applicable guidelines? - What are the key differences between the old and new requirements for technical documentation? - How can you prepare your team to manage the increased workload from these simultaneous updates? - What role does your China agent play in navigating these new regulatory expectations? Sources: - https://www.chinameddevice.com/nmpa-published-57-medical-devices-final-guidelines-on-july-21-2026/ How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory changes like the NMPA's new guidelines. Our team of local experts in China provides regulatory strategy, gap analysis, and technical dossier preparation to ensure your submissions meet the latest requirements. We act as your local representative, managing the entire registration and renewal process. By leveraging advanced AI tools, we streamline dossier compilation and help you access the Chinese market more efficiently. To learn how we can accelerate your market access, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and global device database at https://pureglobal.ai.

  8. Aug 9

    FDA Human Factors Guidance 2026: Navigating New eSTAR Requirements

    The US FDA has finalized its guidance on 'Content of Human Factors Information in Medical Device Marketing Submissions,' introducing a new risk-based framework that became mandatory within the eSTAR portal on August 1, 2026. This episode details the three new risk categories for Human Factors Engineering (HFE) and Usability Engineering (UE) data, explains how they impact 510(k), PMA, and De Novo submissions, and provides practical steps for manufacturers to adapt their processes and documentation to meet these updated requirements. Key Questions: - What is the FDA's finalized guidance on Human Factors for medical device submissions? - When did the new eSTAR template for Human Factors become mandatory? - How does the new risk-based framework categorize devices for HFE/UE data requirements? - What level of Human Factors data is required for a low-risk Category 1 device? - What are the submission requirements for moderate-risk Category 2 and high-risk Category 3 devices? - How should manufacturers update their internal HFE/UE processes to align with the new guidance? - What are the key changes to look for in the eSTAR portal's new Human Factors section? - How can regulatory teams perform a gap analysis against the finalized 2026 guidance? Sources: - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-human-factors-information-medical-device-marketing-submissions - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates - https://www.fdli.org/2026/06/fda-finalizes-human-factors-guidance-for-medical-device-marketing-submissions/ - https://www.raps.org/news-and-articles/news-articles/2026/5/fda-provides-additional-examples-clarity-in-huma How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient regulatory strategies, manage technical dossier submissions using advanced AI, and act as your local representative in over 30 markets. Our experts can help you navigate complex requirements like the FDA's new Human Factors guidance, ensuring your submissions are compliant and minimizing delays. We support the entire product lifecycle, from initial strategy to post-market surveillance, helping you get to market faster and maintain compliance. For more information, visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.

See All (403)

About

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.

Information